1-(3-三氟甲基苯基)咪唑 | 25371-97-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(3-三氟甲基苯基)咪唑
• 英文名称: 1-(3-(trifluoromethyl)phenyl)-1Himidazole
• 英文别名: 1-(3-Trifluoromethylphenyl)imidazole；1-[3-(trifluoromethyl)phenyl]imidazole
• CAS: 25371-97-5
• 化学式: C₁₀H₇F₃N₂
• mdl: MFCD00060487
• 分子量: 212.174
• InChiKey: KZVUPVJLOACZIL-UHFFFAOYSA-N

物化性质

• 沸点：
  70 °C
• 密度：
  1,32 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2933290090
• 安全说明：
  S26,S36/37/39

反应信息

• 作为反应物：
  描述：

  1-(3-三氟甲基苯基)咪唑 在 silver(l) oxide 作用下， 以 四氢呋喃 、 乙二醇乙醚 为溶剂， 反应 24.0h， 生成 2-(2,4-difluorobenzene-6-id-1-yl)pyridine;iridium(3+);1-methyl-3-[3-(trifluoromethyl)benzene-6-id-1-yl]-2H-imidazol-3-ium-2-ide
  参考文献：
  名称：

  N-Heterocyclic Carbenes: Versatile Second Cyclometalated Ligands for Neutral Iridium(III) Heteroleptic Complexes

  摘要：

  With 2-(2,4-difluorophenyl)pyridine (dfppy) as the first cyclometalated ligand and different monoanionic N-heterocyclic carbenes (NHCs) as the second cyclometalated ligands, 16 blue or greenish-blue neutral iridium(III) phosphorescent complexes, (dfppy)(2)Ir(NHC), were synthesized efficiently. The obtained Ir(III) complexes display typical phosphorescence of 455-485 nm with quantum yields up to 0.73. By modifying the phenyl moiety in the NHCs with electron-withdrawing substituents (e.g., -F or -CF3) or replacing it with N-heteroaromatic rings (pyridine or pyrimidine), the HOMO-LUMO gaps are broadened, and the emissions shift to the more blue region accordingly. Furthermore, to extend the application scope of NHCs as the second cyclometalated ligands, five other Ir(III) complexes from blue to red were synthesized with different first cyclometalated ligands. Finally, the organic light-emitting diodes using one blue emitter exhibit a maximum current efficiency of 37.83 cd A(-1), an external quantum efficiency of 10.3%, and a maximum luminance of 8709 cd m(-2). Our results demonstrate that NHCs as the second cyclometalated ligands are good candidates for the achievement of efficient phosphorescent Ir-III complexes and corresponding devices.

  DOI：

  10.1021/ic501949h
• 作为产物：
  描述：

  咪唑 、 3-碘三氟甲苯 在 1,10-菲罗啉 、 (dibenzylidene)acetone copper(I) trifluoromethanesulfonate benzene 、 caesium carbonate 作用下， 以 xylene 为溶剂， 反应 24.0h， 以94%的产率得到1-(3-三氟甲基苯基)咪唑
  参考文献：
  名称：

  铜催化芳基卤化物与咪唑的高效偶联

  摘要：

  铜催化的咪唑的N-芳基化反应可以使用（CuOTf）2 ·苯作为铜源，而Cs 2 CO 3作为二甲苯中的碱在110–125°C下完成。添加1,10-菲咯啉（phen）和反式，反式-二苄基丙酮（dba）对于该方法的成功至关重要。以高收率分离出产物N-芳基咪唑。

  DOI：

  10.1016/s0040-4039(99)00291-9

文献信息

• Highly efficient and practical phosphoramidite–copper catalysts for amination of aryl iodides and heteroaryl bromides with alkylamines and N(H)-heterocycles
  作者：Zhanjin Zhang、Jincheng Mao、Di Zhu、Fan Wu、Huilin Chen、Boshun Wan

  DOI：10.1016/j.tet.2006.02.062

  日期：2006.5

  A highly efficient copper-catalyzed system using phosphoramidite as ligands was applied to N-arylation of alkylamines and N(H)-heterocycles with aryl iodides and heteroaryl bromides. The reactions were carried out in relative mild conditions and good to excellent yields were obtained.

  使用亚磷酰胺作为配体的高效铜催化体系被用于烷基胺和N（H）-杂环与芳基碘化物和杂芳基溴化物的N-芳基化反应。反应在相对温和的条件下进行，并获得了良好的产率。
• Highly Efficient Copper-Catalyzed Formation of <i>N</i>-Aryl Diazoles Using KF/Al₂O₃
  作者：Rahman Hosseinzadeh、Mahmood Tajbakhsh、Mohammad Alikarami

  DOI：10.1055/s-2006-947344

  日期：2006.8

  coupling of aryl iodides with heterocyclic compounds such as diazoles that does not require the use of alkoxide bases is described. The C-N bond forming procedure shows that the combination of air stable Cul and 1,10-phenanthroline in the presence of KF/Al 2 O 3 comprises an extremely efficient and general catalyst system for the N-arylation of aryl iodides. Different functionalized aryl iodides were coupled

  描述了一种无需使用醇盐碱将芳基碘化物与杂环化合物（如二唑）偶联的简单有效方法。CN 键形成过程表明，在 KF/Al 2 O 3 存在下，空气稳定的 Cul 和 1,10-菲咯啉的组合构成了用于芳基碘化物 N-芳基化的极其有效和通用的催化剂体系。使用这种方法将不同的官能化芳基碘与二唑偶联。
• Steric effects on acetate-assisted cyclometallation of <i>meta</i>-substituted <i>N</i>-phenyl and <i>N</i>-benzyl imidazolium salts at [MCl₂Cp*]₂ (M = Ir, Rh)
  作者：David L. Davies、Kuldip Singh、Neringa Tamosiunaite

  DOI：10.1039/d1dt02677a

  日期：——

  acetate-assisted cyclometallation to provide mixtures of ortho and para substituted cyclometallated complexes. The effect of the substituents on the isomer ratios is discussed; steric effects are more important in the 6-membered rings derived from the N-benzyl imidazolium salts than 5-membered rings from the N-phenyl salts. Comparisons are made to steric effects with some other common directing groups.

  间取代的N-苯基、N'-甲基和N-苄基、N'-甲基咪唑鎓盐经历乙酸盐辅助的环金属化以提供邻位和对位取代的环金属化配合物的混合物。讨论了取代基对异构体比例的影响；在衍生自N-苄基咪唑鎓盐的 6 元环中，空间效应比衍生自N-苯基盐的5 元环更重要。与一些其他常见的导向组进行空间效应比较。
• [EN] USE OF UREA VARIANTS AS AFFINITY LIGANDS<br/>[FR] UTILISATION DE VARIANTES D'UREES EN TANT QUE LIGANDS A AFFINITE
  申请人：AMERSHAM BIOSCIENCES AB

  公开号：WO2004039765A1

  公开（公告）日：2004-05-13

  The present invention relates to an IgG-binding compound, which more specifically has affinity for human IgGs of k-type and functional derivatives thereof. More specifically, the compound according to the invention comprises an N,N-alkylated urea moiety located between an aromatic part and another part, which is a linear or cyclic substituted or unsubstituted aliphatic group. The compound binds to a pocket-shaped binding site present on all human IgG k-Fabs, which site is located between the two domains (CH1 and CL) of its constant part. Accordingly, the compound according to the invention is a ligand for human IgGs of k-type, and consequently, the invention also relates to a separation matrix for affinity chromatography, which matrix comprises said compound, as well as to other uses of the compound.

  本发明涉及一种IgG结合化合物，更具体地具有对人类k型IgG及其功能衍生物的亲和力。具体而言，本发明的化合物包括位于芳香部分和另一部分之间的N，N-烷基化脲基团，该另一部分是线性或环状取代或未取代的脂肪族基团。该化合物结合到所有人类IgG k-Fab中存在的口袋状结合位点，该位点位于其常数部分的两个域（CH1和CL）之间。因此，本发明的化合物是人类k型IgG的配体，因此，本发明还涉及一种亲和层析的分离基质，该基质包括所述化合物，以及化合物的其他用途。
• METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES
  申请人：Shakespeare William C.

  公开号：US20140045826A1

  公开（公告）日：2014-02-13

  The invention discloses methods and compositions for treating or preventing neurodegenerative disease by administering a compound of Formula I: or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the variables are defined as herein.

  该发明揭示了通过给予式I化合物或其药学上可接受的盐、溶剂或水合物来治疗或预防神经退行性疾病的方法和组合物，其中变量的定义如本文所述。

表征谱图